Drug news
EU award CE mark approval to ExAblate Neuro System (InsighTec) for treatment of neurological disorders in the brain
The EU has awarded the ExAblate Neuro System, from InsighTec, the European CE mark for the treatment of neurological disorders in the brain including essential tremor, Parkinson's disease and neuropathic pain. InSightec recently received its second ExAblate FDA approval for the treatment of painful bone metastases in patients who are unable or unwilling to undergo radiation. This is in addition to FDA approval and CE mark approval for the treatment of uterine fibroids received in 2004 and 2002 respectively.